| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties M García-Arencibia, S González, E de Lago, JA Ramos, R Mechoulam, ... Brain research 1134, 162-170, 2007 | 353 | 2007 |
| Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis A Cabranes, K Venderova, E De Lago, F Fezza, A Sánchez, L Mestre, ... Neurobiology of disease 20 (2), 207-217, 2005 | 156 | 2005 |
| Cannabinoids and neuroprotection in basal ganglia disorders O Sagredo, M García-Arencibia, E De Lago, S Finetti, A Decio, ... Molecular neurobiology 36, 82-91, 2007 | 118 | 2007 |
| The endocannabinoid system as a target for the treatment of neuronal damage J Fernandez-Ruiz, C Garcia, O Sagredo, M Gómez-Ruiz, E de Lago Expert opinion on therapeutic targets 14 (4), 387-404, 2010 | 114 | 2010 |
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence E de Lago, R de Miguel, I Lastres-Becker, JA Ramos, J Fernández-Ruiz Brain research 1007 (1-2), 152-159, 2004 | 111 | 2004 |
| In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake E De Lago, A Ligresti, G Ortar, E Morera, A Cabranes, G Pryce, M Bifulco, ... European journal of pharmacology 484 (2-3), 249-257, 2004 | 109 | 2004 |
| Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase ML López-Rodríguez, A Viso, S Ortega-Gutiérrez, CJ Fowler, G Tiger, ... Journal of medicinal chemistry 46 (8), 1512-1522, 2003 | 105 | 2003 |
| Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels E de Lago, S Petrosino, M Valenti, E Morera, S Ortega-Gutierrez, ... Biochemical pharmacology 70 (3), 446-452, 2005 | 93 | 2005 |
| Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects E de Lago, M Moreno-Martet, A Cabranes, JA Ramos, J Fernández-Ruiz Neuropharmacology 62 (7), 2299-2308, 2012 | 91 | 2012 |
| UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the … E De Lago, J Fernández-Ruiz, S Ortega-Gutiérrez, A Cabranes, G Pryce, ... European neuropsychopharmacology 16 (1), 7-18, 2006 | 86 | 2006 |
| UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide E de Lago, J Fernández-Ruiz, S Ortega-Gutiérrez, A Viso, ... European journal of pharmacology 449 (1-2), 99-103, 2002 | 81 | 2002 |
| A Sativex®‐like combination of phytocannabinoids as a disease‐modifying therapy in a viral model of multiple sclerosis A Feliú, M Moreno‐Martet, M Mecha, FJ Carrillo‐Salinas, E De Lago, ... British journal of pharmacology 172 (14), 3579-3595, 2015 | 75 | 2015 |
| Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis M Fernández-Trapero, F Espejo-Porras, C Rodríguez-Cueto, JR Coates, ... Disease models & mechanisms 10 (5), 551-558, 2017 | 70 | 2017 |
| Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1G93A Transgenic Mice and Evaluation of a Sativex®‐like Combination of … M Moreno‐Martet, F Espejo‐Porras, J Fernández‐Ruiz, E de Lago CNS neuroscience & therapeutics 20 (9), 809-815, 2014 | 64 | 2014 |
| Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors ML López-Rodrı́guez, A Viso, S Ortega-Gutiérrez, CJ Fowler, G Tiger, ... European journal of medicinal chemistry 38 (4), 403-412, 2003 | 61 | 2003 |
| Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis C Rodríguez-Cueto, I Santos-García, L García-Toscano, F Espejo-Porras, ... Biochemical pharmacology 157, 217-226, 2018 | 59 | 2018 |
| Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment L Martínez-González, C Rodríguez-Cueto, D Cabezudo, F Bartolomé, ... Scientific reports 10 (1), 4449, 2020 | 58 | 2020 |
| Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic … F Espejo‐Porras, L García‐Toscano, C Rodríguez‐Cueto, ... British journal of pharmacology 176 (10), 1585-1600, 2019 | 58 | 2019 |
| Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders F Espejo-Porras, F Piscitelli, R Verde, JA Ramos, V Di Marzo, E de Lago, ... Journal of Neuroimmune Pharmacology 10, 233-244, 2015 | 53 | 2015 |
| Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease E de Lago, P Urbani, JA Ramos, V Di Marzo, J Fernández-Ruiz Brain research 1050 (1-2), 210-216, 2005 | 43 | 2005 |
Javier Fernández-RuizProfesor de Bioquímica, Universidad ComplutenseVerified email at ucm.es
